Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from SanBio Co ( (JP:4592) ).
SanBio Co., Ltd. announced the publication of research in Molecular Therapy demonstrating the potential of their vandefitemcel (SB623) cells to improve cortical excitability in rats with cerebral ischemia. The research suggests that these cells could offer new treatments for neurological disorders, addressing unmet medical needs in central nervous system disorders by promoting neural regeneration and reducing cortical hyperexcitability.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development of regenerative cell medicines. Their primary product line includes modified mesenchymal stem cells designed to address neurological disorders, with a focus on conditions involving neural regeneration and cortical excitability.
YTD Price Performance: 0%
Average Trading Volume: 1,635
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $338M
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.
